The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift …

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significantly
improved the survival of patients with advanced non-small cell lung cancer (NSCLC) …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

Introduction: despite initial dramatic efficacy of EGFR tyrosine kinase inhibitors (TKIs) in
EGFR-mutant lung cancer patients, emergence of acquired resistance is almost inevitable …

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …

Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine …

The discovery of mutations in EGFR significantly changed the treatment paradigm of patients
with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with …